Intravenous infusions of deferoxamine mesylate may be associated with a pulmonary syndrome with features of a hypersensitivity pneumonitis.
Patient selection: continuous intravenous infusion of deferoxamine mesylate
Onset 5 to 10 days after starting the infusion
(3) restrictive pulmonary function pattern
(4) potentially respiratory failure
(1) diffuse interstitial pattern
(1) diffuse alveolar damage
(2) interstitial inflammation with eosinophils, mast cells and lymphocytes
(3) interstitial fibrosis
The diagnosis is supported by:
(1) exclusion of other causes (pulmonary hypertension, infection, etc)
(2) resolution upon discontinuation of the infusion (although this may take time)
(3) relapse on re-exposure
(4) The condition is reported to be dose-dependent.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Pulmonology, Pharmacology, clinical